Safety Alerts Saves Lives
Safety Alerts  
Home Privacy About Us Contact Us Change Preferences

September 13, 2000

Aventis Recalls Certain Lots of Synercid(r) I.V.

Kansas City, MO (SafetyAlerts) - The Food and Drug Administration (FDA) said today that Aventis Pharmaceuticals, Inc., is recalling Synercid(r) I.V. (Quinupristin and Dalfopristin for injection), 500 mg, in 10 mg single dose vials due to lack of assurance of sterility (seal integrity).

This is the first public notice of this Class II recall issued by FDA.

Synercid(r) I.V. (Quinupristin and Dalfopristin for injection), 500 mg, in 10 mg single dose vial, lyophilized, Rx indicated for the treatment of patients with serious or life-threatening infections associated with
vancomycin-resistant Enterococcus faecium (VREF) bacteremia.

NDC #0075-9051-10. Recall #D-450-0.

9G1439 9G1471 9H1854 9J2122 0A1297
9G1440 9G1438 9H1855 9L2562 0A1316
9G1470 9G1441 9H1853 0A1298 0A1419.

Catalytica Pharmaceuticals, Inc., Greenville, North Carolina.

Aventis Pharmaceuticals, Inc., Kansas City, Missouri, by letter dated July 20, 2000. Firm-initiated recall ongoing.

Nationwide, Spain, Canada.

582,130 vials were distributed.

Selected Recent Recalls

Health Professional:

Did you know?
During 2000 there were over
1050 products recalled in the United
States for safety reasons!

How many did you hear about?

Sign-up for SafetyAlerts by Email -
The free internet newsletter that could
some day literally save your life - or
the life of someone you know.

Safety Alerts compiles comprehensive safety recall information for the United States. SafeMail is a free email service to warn consumers of faulty products and contaminated foods. For complete information regarding current recalls, past recalls and timely product warning notification visit:



The information contained herein has been obtained from sources that the Company believes to be reliable, however, the Company has not independently verified or confirmed the information and the recipient acknowledges that no representations or warranties are being made in connection with the use of the information.